RNXTNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
RenovoRx, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.16+0.02 (+1.75%)
Close on Oct 19, 2026
- Market cap
- $54.87M
- P/E (TTM)
- –
- Dividend yield
- –
RenovoRx statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Surgical & Medical Instruments & Apparatus companies for comparison
Valuation
| Measure | RenovoRx | Industry median |
|---|---|---|
| Market Cap | $52.35M | $230.55M |
| Enterprise Value | $42.87M | $202.97M |
| PS Ratio | 26.49 | 3.11 |
| PB Ratio | 5.83 | 3.14 |
| P/TBV Ratio | 5.83 | 4.57 |
Enterprise value
| Measure | RenovoRx | Industry median |
|---|---|---|
| EV / Sales | 21.70 | 2.92 |
Income (trailing twelve months)
| Measure | RenovoRx | Industry median |
|---|---|---|
| Revenue | $1.98M | $102.39M |
| Gross Profit | $1.67M | $60.36M |
| Operating Income | -$13.54M | -$4.31M |
| Net Income | -$12.29M | -$6.57M |
| EBITDA | -$13.54M | -$1.98M |
| EPS (Diluted) | -$0.31 | -$0.07 |
Margins
| Measure | RenovoRx | Industry median |
|---|---|---|
| Gross Margin | 84.4% | 55.1% |
| Operating Margin | -685.2% | -6.04% |
| Profit Margin | -621.7% | -10.5% |
| EBITDA Margin | -685.2% | -2.67% |
| FCF Margin | -604.1% | -0.30% |
Returns
| Measure | RenovoRx | Industry median |
|---|---|---|
| Return on Equity (ROE) | -125.2% | -19.2% |
| Return on Assets (ROA) | -97.8% | -13.3% |
| Return on Capital Employed (ROCE) | -141.2% | -9.07% |
Balance sheet
| Measure | RenovoRx | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $9.48M | $37.33M |
| Net Cash (Debt) | $9.48M | $3.92M |
| Net Cash Per Share | $0.21 | $0.28 |
| Equity (Book Value) | $8.98M | $57.36M |
| Book Value Per Share | $0.20 | $2.81 |
| Tangible Book Value | $8.98M | $10.71M |
| Working Capital | $8.93M | $54.64M |
Financial position
| Measure | RenovoRx | Industry median |
|---|---|---|
| Current Ratio | 5.74 | 2.50 |
| Quick Ratio | 5.29 | 1.54 |
Cash flow (trailing twelve months)
| Measure | RenovoRx | Industry median |
|---|---|---|
| Operating Cash Flow | -$11.87M | -$653.46K |
| Capital Expenditures | -$71.00K | -$3.69M |
| Free Cash Flow | -$11.94M | -$835.02K |
| FCF Per Share | -$0.26 | -$0.02 |
Efficiency
| Measure | RenovoRx | Industry median |
|---|---|---|
| Asset Turnover | 0.16 | 0.59 |
| Inventory Turnover | 0.80 | 2.21 |
| Revenue Per Employee | $116.24K | $322.57K |
| Profits Per Employee | -$722.65K | -$51.88K |
| Employee Count | 17 | 185 |
Dividends and yields
| Measure | RenovoRx | Industry median |
|---|---|---|
| Earnings Yield | -23.5% | -6.91% |
| FCF Yield | -22.8% | -0.56% |
Shares
| Measure | RenovoRx | Industry median |
|---|---|---|
| Shares Outstanding | 45,129,500 | 44,856,700 |
| Shares Change (YoY) | 34.4% | 3.35% |
| Shares Change (QoQ) | 0.15% | 0.27% |
| Float | 42,420,700 | 37,097,900 |
| Shares Held by Insiders | 6.00% | 10.6% |
| Shares Held by Institutions | 20.4% | 63.5% |
Taxes
| Measure | RenovoRx | Industry median |
|---|---|---|
| Income Tax | $2.00K | $1.52M |
Scores
| Measure | RenovoRx | Industry median |
|---|---|---|
| Altman Z-Score | 1.53 | 1.95 |
| Piotroski F-Score | 4 | 5 |
| Beneish M-Score | 19.13 | -2.64 |
Calculated by StockData from RenovoRx's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.